Anacor Pharmaceuticals, Inc. (ANAC)

99.20
NASDAQ
Prev Close 99.20
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio

Why Pfizer, Chevron and Newell Brands Could be Great For Your Portfolio

Pfizer has dominated headlines this year with its failed Allergan merger and its Anacor Pharmaceuticals purchase.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Trending Tickers: IBM, AAPL, WMT, YHOO

Crude prices were helping lift U.S. markets. 

Jim Cramer: Pfizer Will Have a Long Road Ahead With Anacor Buy

Jim Cramer: Pfizer Will Have a Long Road Ahead With Anacor Buy

Jim Cramer says he wouldn't be surprised if Allergan looked at buying Anacor before Pfizer decided to acquire the company for $5.2 billion, including debt.

Opening Bell: Stocks Open Higher on Oil Gains, China Posts Weak Retail Sales

Opening Bell: Stocks Open Higher on Oil Gains, China Posts Weak Retail Sales

U.S. stocks opened higher on Monday, amid rising oil prices.

Anacor Shares Soar on Pfizer's Takeover Bid

Investors rushed to the Palo Alto, Calif.-based drugmaker on news of Pfizer's generous takeover valuation.

Bull Chart of the Day: Anacor Pharmaceuticals

Shares appear ready to push forward after three months of consolidating.

Anacor price target raised at Jefferies

Market Wrap: Progress on Greek Deal Lifts Stocks

Natural gas pops and the VIX falls.

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

A Dangerous Complacency

A Dangerous Complacency

Investors' lack of fear is troubling.

2 Charts to Play the Biotech Countertrend

Looking at technicals going against parabolic moves.

Not a Good Sign

The technical picture demands caution.

Two Speculative Biotech Buys

As M&A action heats up in the sector, consider two names that could shape up to be prime targets.